AVAI BIO, INC. financial statements

Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data AVAI BIO, INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2019	FY2020	FY2021	FY2022	FY2022	FY2024	FY2025	FY2026
Revenue					0.28
Cost of revenue	0	0.46	1.23	0.71	0.28
Gross profit	0	-0.26	-0.02	-0.21	-0.04
Research and development	0	0.03						0.02
General and administrative	0.04	0.23	0.21	0.45	0.23	1.42	0.76	0.79
Operating expenses	0.08	0.33	0.29	0.55	0.32	2.12	1.53	1.48
Operating income	-0.08	0.07	0.3	0.13	-0.35	-2.13	-1.14	-1.75
Other non-operating income					0.01	-0.01
Pre-tax income	-0.08
Income from continuing operations		0.07	0.3	0.13	0.35
Net income	-0.08	-0.07	-0.3	-0.13	-0.35	-2.13	-1.14	-1.75
EBITDA	-0.07	0.11			-0.33	-2.05	-1.07	-1.72
EPS, basic	0.00	0.00	0.00	0.00	0.00	-0.02	-0.01	-0.01
EPS, diluted	0.00	0.00	0.00	0.00	0.00	-0.02	-0.01	-0.01
Shares, basic (weighted)		1.02	26.3	26.3	38.5	86.5	128	138
Shares, diluted (weighted)	4.64	1.02	26.3	26.3	38.5	86.5	128	138
Dividend per share	0.03

Balance sheet

	FY2019	FY2020	FY2021	FY2022	FY2022	FY2024	FY2025	FY2026
Cash and equivalents	0	0.03	0.06	0.03	0.11	0	0.08	0.02
Receivables	0	0	0.06	0				0.06
Other current assets	0	0	0.2	0.13		0.12	0.01	0.01
Total current assets	0.03	0.15	0.62	0.33	0.11	0.12	0.09	0.09
Property, plant and equipment			0	0	0	0		0
Intangible assets	0	0.22			0.13	0.21	0.13	0.11
Other non-current assets	0	0		-0.13	-0.15			0.38
Total assets	0.03	0.42	0.82	0.45	0.24	0.32	0.22	0.57
Accounts payable	0.01	0.05	0.27	0	0.24	1.08	0.89	1.59
Accrued liabilities	0	0.01	0	0
Short-term debt				0.1	0.1		0.03	0.02
Total current liabilities	0.03	0.46	1.14	0.86	0.87	1.79	1.79	3.39
Long-term debt	0.08	0.07
Total liabilities	0.03	-0.04	1.14	0.86	0.87	1.79	1.79	3.39
Total debt				0.1	0.1		0.11	0.02
Paid-in capital	0.02	0.03	0	0.06	0.17	1.37	2.39	2.87
Retained earnings	-0.08	-0.07	0.37	0.5	-0.85	-2.98	-4.12	-5.87
Other comprehensive income			-0.01	0
Shareholders' equity	-0.05	-0.04	-0.33	-0.41	-0.63	-1.47	-1.56	-2.82
Total equity	-0.05	-0.04	-0.33	-0.41	-0.63	-1.47	-1.56	-2.82
Total liabilities and equity	-0.05	0.42	0.82	0.45	0.24	0.32	0.22	0.57
Shares outstanding	5.01	1.06	26.3	26.3	38.5	117	137	153

Cash flow statement

	FY2019	FY2020	FY2021	FY2022	FY2022	FY2024	FY2025	FY2026
Net income	-0.08	-0.07	-0.3	-0.13	-0.35	-2.13	-1.14	-1.75
Depreciation and amortization	0	0.04			0.02	0.08	0.07	0.03
Change in receivables	0	0	-0.03	-0.06	-0
Change in payables	0.01	0.19	-0.22	0.27	0.04	0.84	-0.2	0.71
Cash from operations	-0.08	0.13	0.02	0.54	-0.05	-1.32	-1.16	-1.01
Capital expenditures	-0.02	0
Acquisitions	0	-0.03
Cash from investing	-0.01	-0.27	-0.02	-0.03	-0.03	-0.15
Debt issued							0.01	0.14
Stock issued					0.01	0.03	0.02	0.02
Cash from financing	0.09	0.17	0.03	0.47	0.16	1.36	1.24	0.95
Net change in cash			0.03	-0.03	0.07	-0.11	0.08	-0.06
Free cash flow	-0.11	0.13

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.13 on September 28, 2026.

Profitability

Metric	Value	How it is calculated
Return on assets (ROA)	-352.3%	Net income / average total assets.

Growth

Metric	Value	How it is calculated
Total assets growth, 1y	154.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	33.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-6.8%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	7.7%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	53.0%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	39.3%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.04x	Current assets / current liabilities.
Quick ratio	0.04x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.02x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	507.0%	Total liabilities / total assets.
Working capital	-$3.9M	Current assets - current liabilities.
Goodwill and intangibles / assets	20.1%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$3.4M	Shareholders' equity - goodwill - intangible assets.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.02	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share	-$0.01	Cash from operations / diluted weighted shares.
Book value per share	-$0.02	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$0.02	Tangible book value / shares outstanding.
Cash per share	$0.00	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$19.2M	Share price x shares outstanding.
Enterprise value	$19.2M	Market cap + total debt - cash - short-term investments.
Earnings yield	-14.5%	Net income / market cap (the inverse of P/E).

Was AVAI BIO, INC. profitable in fiscal 2026?

No. It reported a net loss of $1.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to AVAI BIO, INC.